1. Home
  2. CRSP vs HHH Comparison

CRSP vs HHH Comparison

Compare CRSP & HHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$50.24

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Logo Howard Hughes Holdings Inc.

HHH

Howard Hughes Holdings Inc.

HOLD

Current Price

$81.60

Market Cap

4.8B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
HHH
Founded
2013
2010
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
4.8B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
CRSP
HHH
Price
$50.24
$81.60
Analyst Decision
Buy
Buy
Analyst Count
20
2
Target Price
$71.95
$90.00
AVG Volume (30 Days)
1.8M
334.3K
Earning Date
02-11-2026
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
234.52
EPS
N/A
5.10
Revenue
$38,337,000.00
$1,834,033,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1,376.73
$19.38
P/E Ratio
N/A
$15.70
Revenue Growth
N/A
69.81
52 Week Low
$30.04
$61.41
52 Week High
$78.48
$91.07

Technical Indicators

Market Signals
Indicator
CRSP
HHH
Relative Strength Index (RSI) 40.76 50.57
Support Level $49.10 $78.90
Resistance Level $53.00 $83.11
Average True Range (ATR) 3.12 1.80
MACD -0.48 -0.05
Stochastic Oscillator 12.40 54.58

Price Performance

Historical Comparison
CRSP
HHH

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About HHH Howard Hughes Holdings Inc.

Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.

Share on Social Networks: